The uptake of the radiosensitizing compound Ro 03-8799 (Pimonidazole) in human tumors.
The nitroimidazole, Ro 03-8799, has proved unique among the drugs tested as chemical hypoxic cell radiosensitizers because of the preferential concentration which has been observed in tumors. Our accumulation of experience has allowed new analyses to be performed upon 127 samples from 39 patients; 47 samples of normal tissue were also obtained from 26 of these patients. Tissue sampling was performed usually between 20 and 30 minutes after initiation of infusion of Ro 03-8799. By expressing results as tumor: plasma ratios, difficulties in comparison because of differing doses and body sizes, together with a variation in the actual time of sampling, have been avoided. A small portion of each specimen which was analyzed for drug concentration was also examined histologically to give an impression of the percentage of the specimen occupied by tumor cells. Analyses have shown that the average tumor concentration is approximately twice that of normal tissues which have been sampled and four times that in plasma. In 38 breast tumor samples, the concentration of drug varied directly as the proportion occupied by tumor cells. The highest tumor: plasma ratios were seen in samples taken from some samples of malignant melanoma. These findings confirm that a greater potency can be expected for this drug as a radiosensitizer because of its ability to enter tumor cells in high concentration. In drug development programs for chemical sensitizing and cytotoxic agents, drugs which show this phenomenon should be explored.
Dische
S
S
Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, England.
Bennett
M H
MH
Orchard
R
R
Stratford
M R
MR
Wardman
P
P
D001943:Breast Neoplasms / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D008545:Melanoma / Q000097:blood / Q000378:metabolism; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D009593:Nitroimidazoles / Q000493:pharmacokinetics*; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics*; D012004:Rectal Neoplasms / Q000097:blood / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000378:metabolism
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole